{"denoms":[{"counts":[{"groupId":"BG000","value":"299"},{"groupId":"BG001","value":"303"},{"groupId":"BG002","value":"602"}],"units":"Participants"}],"groups":[{"description":"Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.","id":"BG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.2","value":"64.9"},{"groupId":"BG001","spread":"10.2","value":"66.3"},{"groupId":"BG002","spread":"10.7","value":"65.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"78"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"260"},{"groupId":"BG001","value":"264"},{"groupId":"BG002","value":"524"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"164"},{"groupId":"BG002","value":"325"}]}],"title":"0 = fully active"},{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"231"}]}],"title":"1 = restricted in physical activity but ambulatory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"46"}]}],"title":"2 = capable of selfcare"}],"description":"Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is a scale that measures how cancer affects a patient. The scale ranges from 0 (fully active) to 5 (dead). Subjects entering this study were to have an ECOG score of 0, 1 or 2.","paramType":"NUMBER","title":"Baseline Eastern Cooperative Oncology Group (ECOG)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"181"}]}],"title":"Absent"},{"categories":[{"measurements":[{"groupId":"BG000","value":"209"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"421"}]}],"title":"Present"}],"description":"Tumor burden refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body and is also called the tumor load. Randomization was stratified by \"tumor burden\" assessment, ie, the presence of either macroscopic vascular invasion as determined by radiological assessment and/or extra-hepatic spread versus none.","paramType":"NUMBER","title":"Tumor burden","unitOfMeasure":"participants"}]}